Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term ...
Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...
Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the ...
Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...
Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...